Private Advisor Group’s Alterity Therapeutics ATHE Stock Holding History

Private Advisor Group’s Portfolio ATHE Stock Details ATHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-45	Closed	-$1K	–	1692
2020 Q2	$1K	Buy	+45	New	+$286	﹤0.01%	3665

Other funds holding ATHE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SWM

Sugarloaf Wealth Management Duluth, Georgia $529M AUM 14.14% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Private Advisor Group's ATHE Position: Q3 2020 in Review

Private Advisor Group sold out of Alterity Therapeutics (ATHE) in Q3 2020, closing a stake of 45 shares — an estimated $1K sold.

Private Advisor Group first reported a position in ATHE in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 10 funds tracked by Wall St. Rank hold ATHE as of Q3 2020.

Private Advisor Group reported no remaining Alterity Therapeutics position as of Q3 2020 after selling out during the quarter.
Private Advisor Group sold 45 Alterity Therapeutics shares in Q3 2020, an estimated $1K.
Private Advisor Group first reported a position in Alterity Therapeutics in Q2 2020 and held it in 1 quarter.
Private Advisor Group's Alterity Therapeutics position peaked at $1K in Q2 2020.
10 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.